Nasdaq

Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response

MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS).
Medindia

Summer Street Capital Recapitalizes New England Orthotics & Prosthetic Systems ("NEOPS") to Establish Platform for O&P Industry Consolidation

Partnership with accomplished industry CEO Ronald J. Manganiello and one of the leading clinical organizations in the sector will focus on expanding high quality O&P patient care throughout the ...
Business Wire

Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study "Prediction ...
Hartford Business

Branford orthotics-prosthetics vendor recapitalized

New England Orthotic & Prosthetic Systems (NEOPS), based in Branford, has gotten fresh capital from a Buffalo, N.Y. investor to continue operation and expansion of its network of 30 clinics in ...
Stockhouse

Personalis Announces the Launch of NEOPS(TM), a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from ...